Spots Global Cancer Trial Database for contiguous stage ii grade 3 follicular lymphoma

Every month we try and update this database with for contiguous stage ii grade 3 follicular lymphoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Combination Chemotherapy Plus Rituximab in Treating Patients With Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma	NCT00005959	Lymphoma	filgrastim rituximab cyclophosphamid... doxorubicin hyd... prednisone vincristine sul...	18 Years -	National Cancer Institute (NCI)
Monoclonal Antibody Therapy and Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma	NCT00017381	Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Extranodal Marg... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Stage I Adult D... Stage I Adult D... Stage I Grade 1... Stage I Grade 2... Stage I Grade 3... Stage I Mantle ... Stage I Margina... Stage I Small L... Stage III Adult... Stage III Adult... Stage III Grade... Stage III Grade... Stage III Grade... Stage III Mantl... Stage III Margi... Stage III Small... Stage IV Adult ... Stage IV Adult ... Stage IV Grade ... Stage IV Grade ... Stage IV Grade ... Stage IV Mantle... Stage IV Margin... Stage IV Small ... Waldenström Mac...	rituximab cyclophosphamid... filgrastim yttrium Y 90 ib... peripheral bloo...	18 Years - 70 Years	National Cancer Institute (NCI)
Ofatumumab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma	NCT01190449	Lymphoma	ofatumumab	18 Years -	Alliance for Clinical Trials in Oncology
Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Other B-cell Cancers	NCT00003163	Lymphoma Multiple Myelom...	filgrastim sargramostim cyclophosphamid... melphalan autologous bone... peripheral bloo... radiation thera...	18 Years -	National Cancer Institute (NCI)
Combination Chemotherapy in Treating Patients With Lymphoma	NCT00002835	Lymphoma	Bleomycin Sulfa... Filgrastim (G-C... Recombinant Int... Carmustine Cisplatin (CDDP... Cyclophosphamid... Cytarabine (ARA... Etoposide (VP-1... Idarubicin Ifosfamide Leucovorin Calc... Melphalan Methotrexate Methylprednisol... mitoxantrone hy... Vincristine Sul... Peripheral Bloo... Radiation Thera...	15 Years - 59 Years	M.D. Anderson Cancer Center
S8809-S9800-S9911-S9704-A Study of Blood and Tissue Samples From Patients With Follicular Lymphoma Treated With Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone	NCT00933127	Lymphoma	DNA analysis polymerase chai... polymorphism an... laboratory biom...	18 Years -	SWOG Cancer Research Network
Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma	NCT00026429	Leukemia Lymphoma	denileukin dift...	18 Years -	National Cancer Institute (NCI)
Low-Dose Radiation Therapy in Treating Patients With Follicular or Marginal Zone Non-Hodgkin's Lymphoma	NCT00310167	Lymphoma	radiation thera...	18 Years -	University College, London
Rituximab With or Without Lenalidomide in Treating Patients With Previously Untreated Follicular Lymphoma	NCT01307605	Lymphoma	Rituximab lenalidomide	18 Years -	Swiss Group for Clinical Cancer Research
Peripheral Stem Cell Transplantation Plus Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma	NCT00003397	Lymphoma	filgrastim rituximab sargramostim carmustine cisplatin cyclophosphamid... dexamethasone etoposide gemcitabine hyd... melphalan paclitaxel bone marrow abl... peripheral bloo...	18 Years - 75 Years	University of Maryland, Baltimore
Total-Body Irradiation, Tacrolimus, and Mycophenolate Mofetil Plus Bone Marrow Transplantation in Treating Patients With Hematologic Cancers	NCT00003572	Leukemia Lymphoma Multiple Myelom... Myelodysplastic...	peripheral bloo... mycophenolate m... tacrolimus allogeneic bone... radiation thera...	18 Years - 70 Years	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome	NCT00002989	Leukemia Lymphoma Multiple Myelom... Myelodysplastic...	busulfan cyclophosphamid... idarubicin melphalan radiation thera...	16 Years - 60 Years	National Cancer Institute (NCI)
Combination Chemotherapy in Treating Patients With Intermediate-Grade or Immunoblastic Non-Hodgkin's Lymphoma	NCT00002565	Lymphoma	bleomycin sulfa... CHOP regimen cisplatin cyclophosphamid... cytarabine doxorubicin hyd... etoposide idarubicin ifosfamide mesna methylprednisol... mitoxantrone hy... prednisone vincristine sul...	15 Years -	M.D. Anderson Cancer Center
Lenalidomide, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large Cell or Follicular B-Cell Lymphoma	NCT00670358	Lymphoma	pegfilgrastim rituximab cyclophosphamid... doxorubicin hyd... lenalidomide prednisone vincristine sul... polymorphism an... laboratory biom...	18 Years - 120 Years	Mayo Clinic
Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphoma	NCT01045928	Adult Non-Hodgk... Adult Grade III... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Cutaneous B-cel... Extranodal Marg... Nodal Marginal ... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Splenic Margina... Stage I Adult B... Stage I Adult D... Stage I Adult D... Stage I Adult D... Stage I Adult I... Stage I Adult L... Stage I Grade 1... Stage I Grade 2... Stage I Grade 3... Stage I Mantle ... Stage I Margina... Stage I Small L... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Grade... Stage III Grade... Stage III Grade... Stage III Mantl... Stage III Margi... Stage III Small... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Grade ... Stage IV Grade ... Stage IV Grade ... Stage IV Mantle... Stage IV Margin... Stage IV Small ... Waldenstrom Mac...	lenalidomide rituximab polymerase chai... nucleic acid se... polymorphism an... flow cytometry laboratory biom...	18 Years -	Case Comprehensive Cancer Center
Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Stage II, III, or IV Follicular NHL	NCT00732498	Lymphoma	Methylprednisol... Etoposide Cytarabine Cisplatin Rituximab In-Zevalin Y-Zevalin	18 Years -	University of Arizona
Rituximab and Galiximab in Treating Patients With Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma	NCT00117975	Lymphoma	galiximab rituximab	18 Years -	Alliance for Clinical Trials in Oncology
Combination Chemotherapy in Treating Patients With Aggressive Non-Hodgkin's Lymphoma	NCT00005867	Lymphoma	bleomycin sulfa... CHOP regimen cyclophosphamid... doxorubicin hyd... etoposide mitoxantrone hy... prednisolone vincristine sul...	18 Years - 59 Years	National Cancer Institute (NCI)
Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy	NCT00003341	Anemia Leukemia Lymphoma Multiple Myelom...	epoetin alfa quality-of-life...	18 Years -	Memorial Sloan Kettering Cancer Center
Chemotherapy and Total-Body Irradiation Followed by Donor Umbilical Cord Blood Transplant, Cyclosporine, and Mycophenolate Mofetil in Treating Patients With Hematologic Cancer	NCT00290641	Chronic Myelopr... Leukemia Lymphoma Myelodysplastic...	filgrastim graft-versus-tu... cyclophosphamid... cyclosporine fludarabine pho... mycophenolate m... umbilical cord ... radiation thera...	- 45 Years	Masonic Cancer Center, University of Minnesota
S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma	NCT00006721	Lymphoma	rituximab cyclophosphamid... doxorubicin prednisone vincristine tositumomab	18 Years -	SWOG Cancer Research Network
Positron Emission Tomography Using Fludeoxyglucose F 18 in Predicting Response to Treatment in Patients Who Are Receiving Rituximab and Combination Chemotherapy for Newly Diagnosed Non-Hodgkin's Lymphoma	NCT00110006	Lymphoma	rituximab cyclophosphamid... doxorubicin hyd... prednisone vincristine sul... positron emissi... fludeoxyglucose...	18 Years -	Case Comprehensive Cancer Center
Rituximab and GM-CSF in Treating Patients With Newly Diagnosed Follicular B-Cell Lymphoma	NCT00411086	Lymphoma	Rituximab Sargramostim (G...	18 Years -	M.D. Anderson Cancer Center
Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Other B-cell Cancers	NCT00003163	Lymphoma Multiple Myelom...	filgrastim sargramostim cyclophosphamid... melphalan autologous bone... peripheral bloo... radiation thera...	18 Years -	National Cancer Institute (NCI)
Vaccine Therapy and Sargramostim Compared With Placebo and Sargramostim Following Rituximab in Treating Patients With Non-Hodgkin's Lymphoma	NCT00089115	Lymphoma	autologous immu... rituximab sargramostim	18 Years -	National Cancer Institute (NCI)
Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma	NCT00026429	Leukemia Lymphoma	denileukin dift...	18 Years -	National Cancer Institute (NCI)
Involved-Field Radiation Therapy in Treating Patients With Previously Untreated Stage I or Stage II Low-Grade Non-Hodgkin's Lymphoma	NCT00014326	Lymphoma	radiation thera...	18 Years -	European Organisation for Research and Treatment of Cancer - EORTC
S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma	NCT00006721	Lymphoma	rituximab cyclophosphamid... doxorubicin prednisone vincristine tositumomab	18 Years -	SWOG Cancer Research Network
Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Leukemia	NCT00004084	Leukemia Lymphoma	indium In 111 L... yttrium Y 90 ep...	18 Years -	Garden State Cancer Center at the Center for Molecular Medicine and Immunology
Biological Therapy in Treating Patients Undergoing Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation for Hematologic Cancer	NCT00004061	Leukemia Lymphoma Oral Complicati...	filgrastim palifermin cyclophosphamid... etoposide ifosfamide peripheral bloo... quality-of-life... radiation thera...	18 Years - 65 Years	National Cancer Institute (NCI)
Biological Therapy in Treating Patients Undergoing Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation for Hematologic Cancer	NCT00004061	Leukemia Lymphoma Oral Complicati...	filgrastim palifermin cyclophosphamid... etoposide ifosfamide peripheral bloo... quality-of-life... radiation thera...	18 Years - 65 Years	National Cancer Institute (NCI)
Pentostatin and Rituximab in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia	NCT00026351	Leukemia Lymphoma	rituximab pentostatin	18 Years -	National Cancer Institute (NCI)
Rituximab and GM-CSF in Treating Patients With Newly Diagnosed Follicular B-Cell Lymphoma	NCT00411086	Lymphoma	Rituximab Sargramostim (G...	18 Years -	M.D. Anderson Cancer Center
S9911, Combination Chemotherapy Plus Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma	NCT00003784	Lymphoma	CHOP regimen cyclophosphamid... doxorubicin hyd... prednisone vincristine sul... tositumomab and...	18 Years -	SWOG Cancer Research Network
Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma	NCT00003338	Lymphoma	immunoscintigra... technetium Tc 9...	16 Years - 120 Years	Gilead Sciences
Lenalidomide, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large Cell or Follicular B-Cell Lymphoma	NCT00670358	Lymphoma	pegfilgrastim rituximab cyclophosphamid... doxorubicin hyd... lenalidomide prednisone vincristine sul... polymorphism an... laboratory biom...	18 Years - 120 Years	Mayo Clinic
S8809-S9800-S9911TM- Biological Markers in Patients With Follicular Lymphoma Treated on Clinical Trial SWOG-8809, SWOG-9800, or SWOG-9911	NCT00896922	Lymphoma	microarray anal... immunohistochem... laboratory biom...	16 Years - 120 Years	SWOG Cancer Research Network
Rituximab, Combination Chemotherapy, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed Follicular Non-Hodgkin Lymphoma	NCT00637832	Lymphoma	rituximab cyclophosphamid... doxorubicin hyd... prednisolone vincristine sul... yttrium Y 90 ib...	18 Years - 120 Years	University of Southampton
Monoclonal Antibody Therapy and Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma	NCT00017381	Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Extranodal Marg... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Stage I Adult D... Stage I Adult D... Stage I Grade 1... Stage I Grade 2... Stage I Grade 3... Stage I Mantle ... Stage I Margina... Stage I Small L... Stage III Adult... Stage III Adult... Stage III Grade... Stage III Grade... Stage III Grade... Stage III Mantl... Stage III Margi... Stage III Small... Stage IV Adult ... Stage IV Adult ... Stage IV Grade ... Stage IV Grade ... Stage IV Grade ... Stage IV Mantle... Stage IV Margin... Stage IV Small ... Waldenström Mac...	rituximab cyclophosphamid... filgrastim yttrium Y 90 ib... peripheral bloo...	18 Years - 70 Years	National Cancer Institute (NCI)
Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone With or Without Gemcitabine in Treating Patients With Previously Untreated Aggressive Non-Hodgkin's Lymphoma	NCT00079261	Lymphoma Small Intestine...	CHOP regimen cyclophosphamid... doxorubicin hyd... gemcitabine hyd... prednisone vincristine sul...	18 Years - 70 Years	European Organisation for Research and Treatment of Cancer - EORTC
Vaccine Therapy Plus Sargramostim Following Chemotherapy in Previously Untreated Aggressive Non-Hodgkin's Lymphoma	NCT00004197	Lymphoma	keyhole limpet ... sargramostim tumor cell-base... cyclophosphamid... doxorubicin hyd... mitoxantrone hy... prednisone vincristine sul...	18 Years - 120 Years	University of Nebraska
Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma	NCT01216683	Lymphoma	rituximab Bendamustin bortezomib lenalidomide	18 Years -	Eastern Cooperative Oncology Group
A Phase II Study of Allo-HCT for B-Cell NHL Using Zevalin, Fludarabine and Melphalan	NCT00577278	Graft Versus Ho... Leukemia Lymphoma	rituximab fludarabine pho... melphalan sirolimus tacrolimus allogeneic hema... indium In 111 i... yttrium Y 90 ib... laboratory biom...	18 Years - 69 Years	City of Hope Medical Center
Combination Chemotherapy in Treating Patients With Aggressive Non-Hodgkin's Lymphoma	NCT00005867	Lymphoma	bleomycin sulfa... CHOP regimen cyclophosphamid... doxorubicin hyd... etoposide mitoxantrone hy... prednisolone vincristine sul...	18 Years - 59 Years	National Cancer Institute (NCI)
Pegfilgrastim and Rituximab in Treating Patients With Untreated, Relapsed, or Refractory Follicular Lymphoma, Small Lymphocytic Lymphoma, or Marginal Zone Lymphoma	NCT01682044	Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Extranodal Marg... Nodal Marginal ... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Margi... Recurrent Small... Splenic Margina... Stage I Grade 1... Stage I Grade 2... Stage I Grade 3... Stage I Margina... Stage I Small L... Stage III Grade... Stage III Grade... Stage III Grade... Stage III Margi... Stage III Small... Stage IV Grade ... Stage IV Grade ... Stage IV Grade ... Stage IV Margin... Stage IV Small ...	pegfilgrastim rituximab flow cytometry biopsy immunohistochem... western blottin...	19 Years -	Roswell Park Cancer Institute
Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas	NCT02213913	Adult Grade III... B-cell Chronic ... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Cutaneous B-cel... Extranodal Marg... Intraocular Lym... Nodal Marginal ... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Progressive Hai... Small Intestine... Splenic Margina... Stage 0 Chronic... Stage I Adult D... Stage I Adult D... Stage I Adult D... Stage I Adult H... Stage I Adult I... Stage I Chronic... Stage I Grade 1... Stage I Grade 2... Stage I Grade 3... Stage I Mantle ... Stage I Margina... Stage I Small L... Stage II Adult ... Stage II Chroni... Stage II Small ... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Chron... Stage III Grade... Stage III Grade... Stage III Grade... Stage III Mantl... Stage III Margi... Stage III Small... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Chroni... Stage IV Grade ... Stage IV Grade ... Stage IV Grade ... Stage IV Mantle... Stage IV Margin... Stage IV Small ... Testicular Lymp... Untreated Hairy... Waldenström Mac...	lenalidomide etoposide prednisone vincristine sul... doxorubicin hyd... cyclophosphamid... rituximab quality-of-life... laboratory biom...	18 Years -	University of Chicago
Rituximab With or Without Lenalidomide in Treating Patients With Previously Untreated Follicular Lymphoma	NCT01307605	Lymphoma	Rituximab lenalidomide	18 Years -	Swiss Group for Clinical Cancer Research
Ofatumumab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma	NCT01190449	Lymphoma	ofatumumab	18 Years -	Alliance for Clinical Trials in Oncology
Positron Emission Tomography Using Fludeoxyglucose F 18 in Predicting Response to Treatment in Patients Who Are Receiving Rituximab and Combination Chemotherapy for Newly Diagnosed Non-Hodgkin's Lymphoma	NCT00110006	Lymphoma	rituximab cyclophosphamid... doxorubicin hyd... prednisone vincristine sul... positron emissi... fludeoxyglucose...	18 Years -	Case Comprehensive Cancer Center
Rituximab and Galiximab in Treating Patients With Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma	NCT00117975	Lymphoma	galiximab rituximab	18 Years -	Alliance for Clinical Trials in Oncology
Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple Myeloma	NCT02037256	Adult Grade III... B-cell Chronic ... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Cutaneous B-cel... Extranodal Marg... Intraocular Lym... Nodal Marginal ... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Progressive Hai... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Refractory Hair... Refractory Mult... Small Intestine... Splenic Margina... Stage I Adult B... Stage I Adult D... Stage I Adult D... Stage I Adult D... Stage I Adult I... Stage I Adult L... Stage I Grade 1... Stage I Grade 2... Stage I Grade 3... Stage I Mantle ... Stage I Margina... Stage I Multipl... Stage I Small L... Stage II Multip... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Grade... Stage III Grade... Stage III Grade... Stage III Mantl... Stage III Margi... Stage III Multi... Stage III Small... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Grade ... Stage IV Grade ... Stage IV Grade ... Stage IV Mantle... Stage IV Margin... Stage IV Small ... Untreated Hairy... Waldenström Mac...	bortezomib filgrastim autologous hema...	18 Years - 70 Years	Barbara Ann Karmanos Cancer Institute
Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome	NCT00002989	Leukemia Lymphoma Multiple Myelom... Myelodysplastic...	busulfan cyclophosphamid... idarubicin melphalan radiation thera...	16 Years - 60 Years	National Cancer Institute (NCI)
Growth Factor to Prevent Oral Mucositis in Patients With Hematologic Cancer	NCT00004132	Drug/Agent Toxi... Leukemia Lymphoma Multiple Myelom... Oral Complicati... Radiation Toxic...	filgrastim palifermin cyclophosphamid... etoposide ifosfamide quality-of-life... radiation thera...	12 Years - 65 Years	National Cancer Institute (NCI)
Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma	NCT00026429	Leukemia Lymphoma	denileukin dift...	18 Years -	National Cancer Institute (NCI)
Radiolabeled Monoclonal Antibody in the Detection and Staging of Patients With Non-Hodgkin's Lymphoma	NCT00003337	Lymphoma	immunoscintigra... technetium Tc 9...	16 Years - 120 Years	Gilead Sciences
Interleukin-12 Plus Rituximab in Treating Patients With Non-Hodgkin's Lymphoma	NCT00004260	Lymphoma	recombinant int... rituximab	18 Years -	Mayo Clinic
Oral Combination Chemotherapy in Treating Elderly Patients With Intermediate or High-Grade Non-Hodgkin's Lymphomas	NCT00003113	Lymphoma	filgrastim cyclophosphamid... etoposide lomustine procarbazine hy... radiation thera...	60 Years -	Case Comprehensive Cancer Center
Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Stage II, III, or IV Follicular NHL	NCT00732498	Lymphoma	Methylprednisol... Etoposide Cytarabine Cisplatin Rituximab In-Zevalin Y-Zevalin	18 Years -	University of Arizona
SWOG-9239 Reduction of Immunosuppression Plus Interferon Alfa and Combination Chemotherapy in Treating Patients With Malignant Tumors That Develop After Organ Transplant	NCT00002657	Lymphoma Multiple Myelom...	bleomycin sulfa... recombinant int... cyclophosphamid... cytarabine doxorubicin hyd... etoposide methotrexate prednisone vincristine sul... conventional su... radiation thera...	15 Years -	SWOG Cancer Research Network
Rituximab in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Follicular Non-Hodgkin's Lymphoma	NCT00112931	Lymphoma	rituximab No treatment	18 Years - 120 Years	University College, London
Vorinostat and Rituximab in Treating Patients With Indolent Non-Hodgkin Lymphoma	NCT00720876	Lymphoma	rituximab vorinostat	18 Years -	City of Hope Medical Center
Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma	NCT00003338	Lymphoma	immunoscintigra... technetium Tc 9...	16 Years - 120 Years	Gilead Sciences
Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma	NCT00003338	Lymphoma	immunoscintigra... technetium Tc 9...	16 Years - 120 Years	Gilead Sciences
Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone With or Without Gemcitabine in Treating Patients With Previously Untreated Aggressive Non-Hodgkin's Lymphoma	NCT00079261	Lymphoma Small Intestine...	CHOP regimen cyclophosphamid... doxorubicin hyd... gemcitabine hyd... prednisone vincristine sul...	18 Years - 70 Years	European Organisation for Research and Treatment of Cancer - EORTC
Combination Chemotherapy Plus Rituximab in Treating Patients With Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma	NCT00005959	Lymphoma	filgrastim rituximab cyclophosphamid... doxorubicin hyd... prednisone vincristine sul...	18 Years -	National Cancer Institute (NCI)
Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma	NCT00003615	Lymphoma	denileukin dift...	18 Years - 120 Years	Eastern Cooperative Oncology Group
Pegfilgrastim and Rituximab in Treating Patients With Untreated, Relapsed, or Refractory Follicular Lymphoma, Small Lymphocytic Lymphoma, or Marginal Zone Lymphoma	NCT01682044	Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Extranodal Marg... Nodal Marginal ... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Margi... Recurrent Small... Splenic Margina... Stage I Grade 1... Stage I Grade 2... Stage I Grade 3... Stage I Margina... Stage I Small L... Stage III Grade... Stage III Grade... Stage III Grade... Stage III Margi... Stage III Small... Stage IV Grade ... Stage IV Grade ... Stage IV Grade ... Stage IV Margin... Stage IV Small ...	pegfilgrastim rituximab flow cytometry biopsy immunohistochem... western blottin...	19 Years -	Roswell Park Cancer Institute
Combination Chemotherapy Plus Filgrastim With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma	NCT00028717	Lymphoma	filgrastim rituximab cyclophosphamid... doxorubicin hyd... prednisone vincristine sul...	65 Years -	National Cancer Institute (NCI)
Rituximab and Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With B-Cell Non-Hodgkin's Lymphoma	NCT00278408	Lymphoma	filgrastim rituximab cyclophosphamid... doxorubicin hyd... prednisone vincristine sul... radiation thera...	18 Years - 60 Years	German High-Grade Non-Hodgkin's Lymphoma Study Group
S8809-S9800-S9911TM- Biological Markers in Patients With Follicular Lymphoma Treated on Clinical Trial SWOG-8809, SWOG-9800, or SWOG-9911	NCT00896922	Lymphoma	microarray anal... immunohistochem... laboratory biom...	16 Years - 120 Years	SWOG Cancer Research Network
Rituximab and Combination Chemotherapy in Treating Older Patients With Previously Untreated B-Cell Lymphoma	NCT00290667	Lymphoma	pegfilgrastim rituximab cyclophosphamid... doxorubicin hyd... prednisone vincristine sul... pharmacological... radiation thera...	61 Years - 80 Years	Universität des Saarlandes
S8809-S9800-S9911TM- Biological Markers in Patients With Follicular Lymphoma Treated on Clinical Trial SWOG-8809, SWOG-9800, or SWOG-9911	NCT00896922	Lymphoma	microarray anal... immunohistochem... laboratory biom...	16 Years - 120 Years	SWOG Cancer Research Network
Rituximab and Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With B-Cell Non-Hodgkin's Lymphoma	NCT00278408	Lymphoma	filgrastim rituximab cyclophosphamid... doxorubicin hyd... prednisone vincristine sul... radiation thera...	18 Years - 60 Years	German High-Grade Non-Hodgkin's Lymphoma Study Group
Low-Dose Radiation Therapy in Treating Patients With Follicular or Marginal Zone Non-Hodgkin's Lymphoma	NCT00310167	Lymphoma	radiation thera...	18 Years -	University College, London
Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy	NCT00003341	Anemia Leukemia Lymphoma Multiple Myelom...	epoetin alfa quality-of-life...	18 Years -	Memorial Sloan Kettering Cancer Center
Total-Body Irradiation, Tacrolimus, and Mycophenolate Mofetil Plus Bone Marrow Transplantation in Treating Patients With Hematologic Cancers	NCT00003572	Leukemia Lymphoma Multiple Myelom... Myelodysplastic...	peripheral bloo... mycophenolate m... tacrolimus allogeneic bone... radiation thera...	18 Years - 70 Years	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Mycophenolate Mofetil, Tacrolimus, Daclizumab, and Donor Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer	NCT00006350	Leukemia Lymphoma Multiple Myelom... Myelodysplastic...	daclizumab therapeutic all... mycophenolate m... tacrolimus peripheral bloo...	18 Years - 120 Years	University of Maryland, Baltimore

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: